|
|
Prepublished online as a Blood First Edition Paper on February 13, 2003; DOI 10.1182/blood-2002-08-2644.
 Previous Article | Table of Contents | Next Article 
Blood, 1 June 2003, Vol. 101, No. 11, pp. 4285-4289
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial
Bradley C. Ekstrand,
Jennifer B. Lucas,
Steven M. Horwitz,
Zhen Fan,
Sheila Breslin,
Richard T. Hoppe,
Yasodha Natkunam,
Nancy L. Bartlett, and
Sandra J. Horning
From the Departments of Medicine (Oncology), Pathology, and Radiation Oncology, Stanford University School of Medicine, Stanford, CA; and the Department of Medicine (Oncology), Washington University, St Louis, MO.
Lymphocyte-predominant Hodgkin disease (LPHD) is a unique clinical entity characterized by indolent nodal disease that tends to relapse after standard radiotherapy or chemotherapy. The malignant cells of LPHD are CD20+ and therefore rituximab may have activity with fewer late effects than standard therapy. In this phase 2 trial, 22 patients with CD20+ LPHD received 4 weekly doses of rituximab at 375 mg/m2. Ten patients had previously been treated for Hodgkin disease, while 12 patients had untreated disease. All 22 patients responded to rituximab (overall response rate, 100%) with complete response (CR) in 9 (41%), unconfirmed complete response in 1 (5%), and partial response in 12 (54%). Acute treatment-related adverse events were minimal. With a median follow-up of 13 months, 9 patients had relapsed, and estimated median freedom from progression was 10.2 months. Progressive disease was biopsied in 5 patients: 3 had recurrent LPHD, while 2 patients had transformation to large-cell non-Hodgkin lymphoma (LCL). All 3 patients with recurrent LPHD were retreated with rituximab, with a second CR seen in 1 patient and stable disease in 2. Rituximab induced prompt tumor reduction in each of 22 LPHD patients with minimal acute toxicity; however, based on the relatively short response duration seen in our trial and the concerns about transformation, rituximab should be considered investigational treatment for LPHD. Further clinical trials are warranted to determine the optimal dosing schedule of rituximab, the potential for combination treatment, and the possible relationship of rituximab treatment to the development of LCL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Targeting CD20
- Jane N. Winter
Blood 2003 101: 4227.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
L. Nogova, T. Reineke, C. Brillant, M. Sieniawski, T. Rudiger, A. Josting, H. Bredenfeld, R. Skripnitchenko, R.-P. Muller, H.-K. Muller-Hermelink, et al.
Lymphocyte-Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
J. Clin. Oncol.,
January 20, 2008;
26(3):
434 - 439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ansquer, T. Hervouet, A. Devillers, S. de Guibert, T. Gastinne, S. Le Gouill, E. Garin, A. Moreau, F. Kraeber-Bodere, and T. Lamy
18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease
Haematologica,
January 1, 2008;
93(1):
128 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schulz, U. Rehwald, F. Morschhauser, T. Elter, C. Driessen, T. Rudiger, P. Borchmann, R. Schnell, V. Diehl, A. Engert, et al.
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Blood,
January 1, 2008;
111(1):
109 - 111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Venugopal and S. A. Gregory
Lymphoproliferative disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
265 - 297.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell and J. O. Armitage
Management of Hodgkin Lymphoma
Mayo Clin. Proc.,
March 1, 2006;
81(3):
419 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Nogova, T. Rudiger, and A. Engert
Biology, Clinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Hematology,
January 1, 2006;
2006(1):
266 - 272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Nogova, T. Reineke, H. T. Eich, A. Josting, H. K. Muller-Hermelink, K. Wingbermuhle, C. Brillant, A. Gossmann, J. Oertel, M. V. Bollen, et al.
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)
Ann. Onc.,
October 1, 2005;
16(10):
1683 - 1687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Re, R. K. Thomas, K. Behringer, and V. Diehl
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
Blood,
June 15, 2005;
105(12):
4553 - 4560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Feugier, E. Labouyrie, M. Djeridane, A. Jenabian, V. Dubruille, C. Berthou, C. Ghandour, B. Desablens, Y. Chait, P. Casassus, et al.
Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation
Blood,
November 1, 2004;
104(9):
2675 - 2681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl, H. Stein, M. Hummel, R. Zollinger, and J. M. Connors
Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hematology,
January 1, 2003;
2003(1):
225 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
